AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides
- Conditions
- Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Interventions
- Drug: ABT-143
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 474
- Registration Number
- NCT00812955
- Locations
- 🇺🇸
Site Reference ID/Investigator# 12495, Carmichael, California, United States
🇺🇸Site Reference ID/Investigator# 12668, Delray Beach, Florida, United States
🇺🇸Site Reference ID/Investigator# 12554, Berlin, New Jersey, United States
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
- Conditions
- Asthma
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2011-12-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 579
- Registration Number
- NCT00812357
- Locations
- 🇫🇷
Research Site, Le Chesnay, Yvelines, France
Excretion of Radiolabelled AZD0837
- Conditions
- Healthy
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00812643
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00812045
- Locations
- 🇪🇸
Research Site, Madrid, Comunidad de Madrid, Spain
Pediatric Bipolar Depression
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 193
- Registration Number
- NCT00811473
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
- Conditions
- Schizophrenia
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 490
- Registration Number
- NCT00809731
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00808678
- Locations
- 🇺🇸
Site Reference ID/Investigator# 14762, Orlando, Florida, United States
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2010-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 369
- Registration Number
- NCT00807937
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 725
- Registration Number
- NCT00808249
- Locations
- 🇺🇸
Research Site, Middleton, Wisconsin, United States
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 340
- Registration Number
- NCT00806754
- Locations
- 🇺🇸
Altana/Nycomed, Milwaukee, Wisconsin, United States